product name Betamethasone Valerate
Description: Betamethasone Valerate (also known as BV or BET, betamethasone 17-valerate) is a moderately potent glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. Betamethasone valerate is a commonly used anti-inflammatory corticosteroid, used to manufacture dermatological drug products for topical applications. Its IC50 in normal rats is 3.4±0.5 nM. Betamethasone Valerate can reduce glucose-6-phosphate dehydrogenase (G-6-PDH) activity in vitro.
References: Spectrochim Acta A Mol Biomol Spectrosc. 2015 Apr 5;140:294-304; Br Med J. 1971 Jul 10;3(5766):84-6; J Pharm Biomed Anal. 2011 Jan 5;54(1):242-7.
476.58
Formula
C27H37FO6
CAS No.
2152-44-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 95 mg/mL (199.3 mM)
Water: <1 mg/mL
Ethanol: 58 mg/mL (121.7 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19422869
| In Vitro |
In vitro activity: The presence of BV at a concentration of 4.6 mM/l provoked a still further diminuition of the G-6-PDH-activity of human skin homogenates that followed the incubation for 120 min at 37°C in media containing 5% dimethylformamide and in which the concentration of G-6-PDH changed from about 55 mU/ml to 9 mU/ml. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Compared with sodium cromoglycate (SCG, 80mg daily), treatment of betamethasone valerate (BV, 800μg daily) for 4 weeks made children requiring bronchodilators for perennial asthma significantly require less bronchodilator drugs, and have fewer symptoms and higher daily peak expiratory flow rates. Compared with coal tar (10% LCD) cream, after a 2 week wash-out period, treatment with betamethasone valerate cream (0.1%) twice daily for 6 weeks made patients with stable, mild-moderate plaque psoriasis get more mean reduction of PASI score from baseline. The final effect of betamethasone valerate was significantly greater clearance and improvement . |
| Animal model | |
| Formulation & Dosage | |
| References | Spectrochim Acta A Mol Biomol Spectrosc. 2015 Apr 5;140:294-304; Br Med J. 1971 Jul 10;3(5766):84-6; J Pharm Biomed Anal. 2011 Jan 5;54(1):242-7. |
